▶ EOPatch resolves unmet needs in conventional insulin delivery and insulin pumps
▶ With its 3.5-day cycle, twice-a-week routine will improve compliance
▶ EOPatch will be available to all users through Huons from early April
On March 29, EOFlow, a company specializing in wearable drug delivery solutions, announced that it officially launches its wearable insulin pump “EOPatch” in Korea, which is the first in Korea and the second in the world to be commercially available.
EOPatch is a disposable wearable insulin pump which is used to continuously deliver insulin in blood glucose control. It is the world’s second wearable disposable insulin pump to be commercially available.
With EOPatch, EOFlow enters the wearable disposable insulin pump market, providing an alternative to users in the market monopolized by Insulet Corporation for the past 16 years. EOFlow has made its EOPatch much easier to use than the existing insulin pumps. EOPatch’s key advantages include ▲ Wireless/tubeless ▲ Small and light design that drastically reduces size and weight ▲ Waterproof ▲ Long wear time (3.5 days) to allow twice-a-week compliance ▲ Faster needle insertion than other wearable solutions for reduced insertion pain.
"Insulin delivery devices used for type 1 diabetes, advanced type 2 diabetes and gestational diabetes have evolved from syringes to pens to regular insulin pumps," Professor Cheol-Young Park from the division of endocrinology and metabolism, department of Internal medicine at Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine said, “Wearable insulin pumps such as EOPatch are a key innovation driver that brings in another paradigm shift.”
"EOPatch will improve insulin users’ quality of life (QoL) with its key competitiveness such as improved compliance and cost advantage,” he added.
The EOPatch insulin management system consists of a wearable insulin pump ‘Patch,’ a smartphone like controller ‘ADM,’ and a diabetes management software ‘EOBridge.' An ADM is connected to a patch via Bluetooth. Insulin injection can be controlled from an ADM and up to 90 days of injection history is stored. Data is synchronized to the EOBridge app or web to be analyzed and shared with guardians or medical personnel.
"We are very excited to present our first wearable insulin pump in Korea," Jesse Kim, founding CEO of EOFlow said, "We are confident that EOPatch will overcome the limitations of conventional insulin pumps and position itself as an innovative digital medical device to address the unmet needs in insulin delivery."
"Starting with the full launch of EOPatch in Korea, the company will do its best to make its product available in the international diabetes market as soon as possible. Our aim is to make our product available and accessible to all the MDI (Multiple Daily Injection) insulin users around the world,” he added.
EOFlow is making its first delivery of EOPatch units to its exclusive distribution partner in Korea Huons on March 29, and the units will be sold through Huons’ online shop from early April.
▣ For all Investment and Press Inquiries, please contact firstname.lastname@example.org